Omega Diagnostics Group PLC Annual Report and Group Financial Statements 2017 Because health matters PAGE TITLE continued Sub title Operational highlights • Scottish Enterprise grant funding of £1.8 million secured towards planned expansion of Allersys ® menu • CE mark achieved for 41 allergens to run on IDS-iSYS platform • Four new Allergodip ® panels now optimised • Recruitment of skilled project managers and leaders into scientific teams • Food intolerance division continues its strong performance • Formal design freeze attained with our VISITECT ® CD4 test • CE mark achieved for VISITECT ® tests to be manufactured at our facility in Pune * The Group defines adjusted profit before taxation as statutory profit before tax and amortisation of intangible assets, share-based payment charges and IFRS-related discount charges.